Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Net Margin (2021 - 2025)

Oncology Institute (TOI) has disclosed Net Margin for 5 consecutive years, with 10.11% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 602.0% year-over-year to 10.11%, compared with a TTM value of 13.28% through Sep 2025, up 452.0%, and an annual FY2024 reading of 13.47%, up 746.0% over the prior year.
  • Net Margin was 10.11% for Q3 2025 at Oncology Institute, up from 14.2% in the prior quarter.
  • Across five years, Net Margin topped out at 34.96% in Q1 2022 and bottomed at 39.37% in Q1 2023.
  • Average Net Margin over 5 years is 11.64%, with a median of 14.2% recorded in 2025.
  • The sharpest move saw Net Margin soared 2323bps in 2022, then tumbled -7433bps in 2023.
  • Year by year, Net Margin stood at 18.99% in 2021, then rose by 19bps to 15.41% in 2022, then tumbled by -42bps to 21.86% in 2023, then soared by 51bps to 10.8% in 2024, then increased by 6bps to 10.11% in 2025.
  • Business Quant data shows Net Margin for TOI at 10.11% in Q3 2025, 14.2% in Q2 2025, and 18.76% in Q1 2025.